Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Pulmonary artery

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    291 result(s) found for: Pulmonary artery. Displaying page 9 of 15.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    EudraCT Number: 2017-003342-25 Sponsor Protocol Number: P170604J Start Date*: 2018-09-07
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Long-term treatment of cancer associated VTE Optimal dose of apixaban API-CAT STUDY for APIxaban Cancer Associated Thrombosis
    Medical condition: Patients with breast, prostate, and colorectal active cancer, with objectively documented index event of symptomatic or incidental proximal DVT or symptomatic or incidental PE, after 6 months of an...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10076654 Cancer-associated thrombosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) PL (Ongoing) ES (Restarted) GB (GB - no longer in EU/EEA) BE (Completed) GR (Completed) AT (Ongoing) NL (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003125-39 Sponsor Protocol Number: TRI-08892 Start Date*: 2020-10-12
    Sponsor Name:Thrombosis Research Institute
    Full Title: Early thromboprophylaxis in COVID-19 (ETHIC trial): an open label, randomized phase IIIb trial of community-based prophylactic low-molecular-weight heparin (LMWH) versus standard of care (no enoxap...
    Medical condition: Confirmed diagnosis of SARS-CoV-2 with symptomatic COVID-19 infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002847-28 Sponsor Protocol Number: CRLX030A2208 Start Date*: 2014-06-26
    Sponsor Name:Novartis Pharma Services AG
    Full Title: Multicenter, open-label, dose escalation study to evaluate safety, tolerability and pharmacokinetics of RLX030 in addition to standard of care in pediatric patients from birth to <18 years of age, ...
    Medical condition: acute heart failure
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004849 10000803 Acute heart failure LLT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-003674-96 Sponsor Protocol Number: CV185-036 Start Date*: 2007-07-27
    Sponsor Name:Bristol Myers Squibb
    Full Title: A Phase 3 Randomized, Double-blind, Parallel-group, Multi-center Study of the Safety and Efficacy of Apixaban for Prophylaxis of Venous Thromboembolism in Acutely Ill Medical Subjects During and Fo...
    Medical condition: Total Venous thromboembolism (VTE), defined as the combination of fatal or nonfatal pulmonary embolism, symptomatic deep vein thrombosis (DVT), and asymptomatic proximal DVT.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051055 Deep vein thrombosis LLT
    9.1 10037377 Pulmonary embolism LLT
    9.1 10049918 Deep venous thrombosis proximal LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed) NL (Completed) CZ (Completed) AT (Completed) FR (Completed) DK (Completed) HU (Completed) DE (Completed) IT (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-005223-90 Sponsor Protocol Number: PULSE-PAH-004 Start Date*: 2016-07-12
    Sponsor Name:Bellerophon Pulse Technologies LLC
    Full Title: A PHASE 3, PLACEBO CONTROLLED, DOUBLE-BLIND, RANDOMIZED, CLINICAL STUDY TO DETERMINE EFFICACY, SAFETY AND TOLERABILITY OF PULSED, INHALED NITRIC OXIDE (iNO) VERSUS PLACEBO IN SYMPTOMATIC SUBJECTS W...
    Medical condition: Pulmonary Arterial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) PT (Prematurely Ended) BE (Prematurely Ended) CZ (Prematurely Ended) NL (Prematurely Ended) AT (Prematurely Ended) HR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-018863-40 Sponsor Protocol Number: BAY63-2521/15096 Start Date*: 2010-07-16
    Sponsor Name:Bayer HealthCare AG
    Full Title: An interaction study to evaluate changes in blood pressure following 1, 1.5, 2, and 2.5 mg riociguat tid (dose titration) compared to placebo treatment on the background of stable sildenafil pretre...
    Medical condition: Pulmonary arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) CZ (Prematurely Ended) PL (Prematurely Ended) AT (Completed) IT (Prematurely Ended) GB (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-006337-19 Sponsor Protocol Number: R5381-HF-2159 Start Date*: 2022-06-08
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of REGN5381, an NPR1 Agonis...
    Medical condition: Heart Failure
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10010684 Congestive heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-011150-17 Sponsor Protocol Number: AMB112565 Start Date*: 2010-08-26
    Sponsor Name:GlaxoSmithKline R&D Ltd
    Full Title: AMBITION: A Randomised, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects with Pulmonary Arterial Hypertension
    Medical condition: Pulmonary arterial hypotension
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) ES (Completed) BE (Completed) SE (Completed) GB (Completed) AT (Completed) GR (Completed) DE (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2006-000658-27 Sponsor Protocol Number: D5130C05262 Start Date*: 2006-12-12
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute C...
    Medical condition: non-ST and ST elevation acute coronary syndromes (ACS)
    Disease: Version SOC Term Classification Code Term Level
    9 10011085 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FI (Completed) PT (Completed) HU (Completed) DE (Completed) FR (Completed) SE (Completed) AT (Completed) NL (Completed) DK (Completed) SK (Completed) BE (Completed) CZ (Completed) GR (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-004972-20 Sponsor Protocol Number: PST2744-DM-04-012 Start Date*: 2007-01-18
    Sponsor Name:Sigma-Tau i.f.r. S.p.A.
    Full Title: A Phase II Study to assess the hemodynamic effects of ISTAROXIME, a novel lusinotropic agent, in patients hospitalized with worsening heart failure and a reduced left ventricular systolic function.
    Medical condition: Chronic heart failure and left ventricular systolic dysfunction
    Disease: Version SOC Term Classification Code Term Level
    8.1 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003414-40 Sponsor Protocol Number: LTI-201 Start Date*: 2019-01-31
    Sponsor Name:Liquidia Technologies, Inc.
    Full Title: A Two Part, Phase 2 Open-label, Multi-Centre, Dose Escalation Hemodynamic Study to Evaluate Dose-Response and Safety of Inhaled LIQ861 (Treprostinil) in Pulmonary Arterial Hypertension (WHO Group 1...
    Medical condition: Pulmonary Arterial Hypertension (WHO Group 1)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10077739 Pulmonary arterial hypertension WHO functional class I LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-001830-12 Sponsor Protocol Number: CTHC007 Start Date*: 2015-11-02
    Sponsor Name:University Medical Center of the Johannes Gutenberg University Mainz
    Full Title: Safety and Efficacy of Low Molecular Weight Heparin for 72 Hours Followed by Dabigatran for the Treatment of Acute Intermediate-Risk Pulmonary Embolism.
    Medical condition: Acute Intermediate-Risk Pulmonary Embolism
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10037379 Pulmonary embolism and thrombosis HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Prematurely Ended) BE (Completed) NL (Completed) AT (Completed) SI (Completed) FR (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-004783-22 Sponsor Protocol Number: 67896049PAH4005 Start Date*: 2020-12-03
    Sponsor Name:ACTELION Pharmaceuticals Ltd.
    Full Title: A PRospective, Multicenter, Single-arm, Open label, Phase 4 Study of the Effects of Selexipag on RighT Ventricular RemOdeling in Pulmonary Arterial Hypertension Assessed by Cardiac Magnetic REsonan...
    Medical condition: Pulmonary Arterial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) GB (GB - no longer in EU/EEA) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-009366-13 Sponsor Protocol Number: TDE-PH-308 Start Date*: 2009-09-02
    Sponsor Name:United Therapeutics Corporation
    Full Title: A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects with Pulmonary Arterial Hyp...
    Medical condition: Pulmonary Arterial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed) BE (Completed) AT (Completed) DE (Completed) ES (Completed) SE (Completed) PT (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-003093-40 Sponsor Protocol Number: FADOI_032016 Start Date*: 2017-03-10
    Sponsor Name:FONDAZIONE FADOI
    Full Title: Apixaban for the treatment of venous thromboembolism in patients with cancer: a prospective randomized open blinded end point (PROBE) study- the CARAVAGGIO study.
    Medical condition: Venous thromboembolism in cancer patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) GB (GB - no longer in EU/EEA) DE (Completed) ES (Completed) PT (Completed) PL (Completed) NL (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001758-14 Sponsor Protocol Number: 201677 Start Date*: 2015-12-18
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients with Giant Cell Arteritis
    Medical condition: Giant Cell Arteritis (GCA)
    Disease: Version SOC Term Classification Code Term Level
    19.1 10047065 - Vascular disorders 10047116 Vascular inflammations HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended) BG (Prematurely Ended) HU (Prematurely Ended) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-002707-16 Sponsor Protocol Number: FIBHGM-ECNC004-2011 Start Date*: 2014-01-09
    Sponsor Name:Fundacion para la investigación Biomédica del hospital Gregorio Marañón
    Full Title: " SILDENAFIL IN THE POST-CARDIAC SURGERY IN CHILDREN: IVORY STUDY"
    Medical condition: Postoperative pulmonary artery hypertension
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004855 10065150 Associated with pulmonary arterial hypertension LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-005348-28 Sponsor Protocol Number: ARD-3150-1201 Start Date*: 2014-05-06
    Sponsor Name:Aradigm Corporation
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pulmaquin® in the Management of Chronic Lung Infections with Pseudomonas aeruginosa in Subje...
    Medical condition: Chronic lung infections with Pseudomonas aeruginosa in subjects with non-cystic fibrosis bronchiectasis.
    Disease: Version SOC Term Classification Code Term Level
    18.0 10021881 - Infections and infestations 10057582 Lung infection pseudomonal PT
    18.0 100000004855 10006446 Bronchiectasis NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) IT (Completed) ES (Completed) LV (Completed) RO (Completed) IE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2006-004495-13 Sponsor Protocol Number: BAY 59-7939/11702 Start Date*: 2007-03-12
    Sponsor Name:Bayer Healthcare AG
    Full Title: Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism.
    Medical condition: Treatment and secondary prevention of venous thromboembolism in patients with acute symptomatic deep- vein thrombosis or pulmonary embolism
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) SE (Completed) FR (Completed) DE (Completed) FI (Completed) DK (Completed) HU (Completed) AT (Completed) IT (Completed) GB (Completed) CZ (Completed) NL (Completed) IE (Completed) LT (Completed) EE (Completed) LV (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2012-004117-14 Sponsor Protocol Number: SPON1037-11 Start Date*: 2013-04-15
    Sponsor Name:Cardiff University
    Full Title: A feasibility study to inform the design of a randomised controlled trial to identify the most clinically and cost effective length of Anticoagulation with Low molecular weight heparin In the treat...
    Medical condition: Cancer Associated Thrombosis (CAT). Venous thromboembolism (VTE). Deep vein thrombosis (DVT). Pulmonary embolus (PE).
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004865 10049910 Thromboembolism prophylaxis LLT
    14.1 100000004866 10066899 Venous thromboembolism LLT
    14.1 100000004865 10013880 DVT prophylaxis LLT
    14.1 100000004855 10037380 Pulmonary embolus LLT
    14.1 100000004866 10043566 Thromboembolism LLT
    14.1 100000004855 10037436 Pulmonary thromboembolism LLT
    14.1 100000004865 10049909 Venous thromboembolism prophylaxis LLT
    14.1 100000004866 10013877 DVT LLT
    14.1 100000004866 10013878 DVT of calf LLT
    14.1 100000004866 10013879 DVT of legs LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jun 05 22:48:21 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA